Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442311 · ClinicalTrials.gov registry record · NA
Directly Observed Hepatitis C Treatment in Methadone Clinics
A NA study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT01442311 is a NA study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 80 participants.
The verdict
NCT01442311, a NA study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
Drug users account for a disproportionately large burden of hepatitis C virus (HCV) infection. However, HCV treatment adherence rates in drug users may be suboptimal in patients who use drugs regularly during HCV treatment. Because HCV treatment is most effective when patients adhere to at least 80% of the prescribed treatment regimen, interventions to improve HCV treatment adherence need to be developed and evaluated. The investigators designed the HCV DOT trial to test the efficacy of two versions of modified directly observed HCV therapy provided on-site at a methadone clinic. The primary objective of this trial is to determine whether enhanced DOT with both pegylated interferon alfa-2a plus ribavirin (PEG/RBV-DOT) is more efficacious than standard DOT with weekly provider-administered pegylated interferon (PEG-DOT) and self-administered ribavirin for increasing adherence and improving HCV treatment outcomes. The investigators hypothesize that PEG/RBV-DOT is associated with increased adherence and rates of sustained viral response compared with PEG-DOT.
Interventions
- OTHER enhanced DOT (both pegylated interferon alfa-2a and ribavirin)
- OTHER standard DOT (PEG-DOT control arm)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2007-10 |
| Est. Completion | 2013-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01442311
The ClinicalTrials.gov registry entry for NCT01442311 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which enhanced DOT (both pegylated interferon alfa-2a and ribavirin) is the first listed.
NCT01442311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01442311 about?
NCT01442311 is a clinical study titled "Directly Observed Hepatitis C Treatment in Methadone Clinics". Drug users account for a disproportionately large burden of hepatitis C virus (HCV) infection. However, HCV treatment adherence rates in drug users may be suboptimal in patients who use drugs regularly during HCV treatment. Because HCV treatment is most effective when patients adhere to at least 80%...
What is the current status of trial NCT01442311?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2007-10. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01442311?
The interventions under investigation include: enhanced DOT (both pegylated interferon alfa-2a and ribavirin) (OTHER), standard DOT (PEG-DOT control arm) (OTHER).
Who is sponsoring clinical trial NCT01442311?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.